Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11512276 | 0.85 | HDAC1 (0.59) | SHMT2RAB9APOLBALDH1A1HDAC1 | |
| SCHEMBL5396991 | 0.85 | MEN1 (0.53) | SHMT2RAB9APOLBHDAC4MEF2D | |
| SCHEMBL7835892 | 0.82 | RAB9A (0.57) | RAB9APOLBALDH1A1LMNAL3MBTL1 | |
| SCHEMBL13054791 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1HDAC1HDAC8HDAC6LMNA | |
| SCHEMBL9729001 | 0.82 | SMN1; SMN2 (0.52) | RAB9APOLBALDH1A1HDAC1HDAC8 | |
| SCHEMBL11935975 | 0.82 | SHMT2 (0.57) | SHMT2POLBHDAC4MEF2DALDH1A1 | |
| SCHEMBL9337417 | 0.82 | SHMT2 (0.57) | SHMT2RAB9APOLBHDAC4MEF2D | |
| SCHEMBL10560340 | 0.82 | SHMT2 (0.61) | SHMT2RAB9APOLBHDAC4MEF2D | |
| SCHEMBL23227889 | 0.81 | ALDH1A1 (0.48) | POLBALDH1A1HDAC1HDAC8HDAC6 | |
| SCHEMBL8773039 | 0.80 | ALDH1A1 (0.74) | SHMT2RAB9AALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1384712-B1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BREWERY (JP) | 2007-03-07 | — | — | EP | disclosed |
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-01 | — | — | US | disclosed |
| US-7169789-B2 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6797823-B1 | Quinoline derivatives and quinazoline derivatives | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1384712-A1 | Derivatives of N-((quinolinyl)oxy)-phenyl)-urea and N-((quinazolinyl)oxy)-phenyl)-urea with antitumor activity | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1153920-B1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BREWERY (JP) | 2003-10-29 | — | — | EP | disclosed |
| EP-1153920-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES | KIRIN BEER KABUSHIKI KAISHA (JP) | 2001-11-14 | — | — | EP | disclosed |
| EP-0401167-B1 | Process for the preparation of titanocenes with o,o'-difluoro ligands | CIBA GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| EP-0598962-A1 | Imidazole derivatives as calcium channel blockers | NEUROSEARCH A/S (DK) | 1994-06-01 | — | — | EP | disclosed |
| US-5296493-A | Analgesics or antiischemics | NEUROSEARCH A/S (DK) | 1994-03-22 | — | — | US | disclosed |
| US-5075467-A | Reacting organotitanium halide with lithium amide | CIBA-GEIGY CORPORATION (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0401167-A2 | Process for the preparation of titanocenes with o,o'-difluoro ligands | CIBA-GEIGY AG (CH) | 1990-12-05 | — | — | EP | disclosed |
| US-4152452-A | N-BENZYLANILINE AND DERIVATIVES | WILLIAM H. RORER, INC. (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027318-A1 | Quinoline derivatives and quinazoline derivatives | CYTH3, NQO2, NRAS | SHMT2 3301/4885RAB9A 139/4885POLB 2988/4885 |
| US-20040209905-A1 | Quinoline derivatives and quinazoline derivatives | RABL3, NRAS, CYTH3 | SHMT2 2974/4885RAB9A 189/4885POLB 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.